Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Schrappe, M; Valsecchi, M G; Bartram, C R; Schrauder, A; Panzer-Grümayer, R; Möricke, A; Parasole, R; Zimmermann, M; Dworzak, M; Buldini, B; Reiter, A; Basso, G; Klingebiel, T; Messina, C; Ratei, R; Cazzaniga, G; Koehler, R; Locatelli, F; Schäfer, B W; Aricò, M; Welte, K; van Dongen, J J M; Gadner, H; Biondi, A; Conter, V (2011). Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 118(8):2077-2084.

Tallen, G; Ratei, R; Mann, G; Kaspers, G; Niggli, F; Karachunsky, A; Ebell, W; Escherich, G; Schrappe, M; Klingebiel, T; Fengler, R; Henze, G; von Stackelberg, A (2010). Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Journal of Clinical Oncology, 28(14):2339-2347.

Möricke, A; Reiter, A; Zimmermann, M; Gadner, H; Stanulla, M; Dördelmann, N; Löning, L; Beier, R; Ludwig, W D; Ratei, R; Harbott, J; Boos, H; Mann, G; Niggli, F; Feldges, A; Henze, G; Welte, K; Beck, J D; Klingebiel, T; Niemeyer, C; Zintl, F; Bode, U; Urban, C; Wehinger, H; Niethammer, D; Riehm, H; Schrappe, M (2008). Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 111(9):4477-4489.

This list was generated on Wed Jun 19 08:50:52 2019 CEST.